Archive for July, 2003

h1

105897573751928767

July 23, 2003

Antibiotics, The Next Generation
Few things are as inexorable as the march of bacterial resistance. When a person or animal is given an antibiotic, it kills enough pathogens to cure the illness. But bacteria that have mutated so they can resist the drug survive. The next time these bacteria cause an infection, the antibiotic is less likely to work. But that is drawing some biotech companies into the antibiotic research.

Advertisements
h1

105890005193409470

July 22, 2003

The War against ‘Viagra’

The US Food and Drug Administration has announced plans to fight counterfeit drugs. The FDA will introduce technology that could show at a glance if drugs are real, such as watermarks or electronic tags. It will also tighten requirements for drug wholesalers so it’s tougher to sneak counterfeits into legitimate supplies.

h1

105888966303914343

July 22, 2003

BIO leader hits proposal for drug price regulation

The Cambridge-based chairman of the nation’s largest biotech organization is strongly opposing any federal controls in drug pricing if a prescription drug component is added to Medicare.

“It’s price controls or innovation; you can’t have both,” said Richard Pops, who recently was elected to head the board of directors of the Biotechnology Industry Organization (BIO), a Washington-based information and lobbying group. Pops is CEO of Alkermes Inc. in Cambridge.

h1

105888896679597884

July 22, 2003

Biotech industry in survival mode
Restructuring, retrenching and reinventing themselves, Bay Area biotechnology firms are adapting to weather the economic downturn.

“We’ve noticed (biotech companies) will abandon one or two research products and in the process may have discovered something of more use, readjusting their core competency to find something marketable today, rather than long term”

h1

105887996005315557

July 22, 2003

The genetically-modified food fight
Once again, Europe and the U.S. are at loggerheads. This time, they’re fighting over food, not foreign policy. On July 2, the European Parliament passed legislation calling for detailed labeling of genetically modified (GM) food products.

h1

105884542924508100

July 21, 2003

No simple generic answer
Unlike pills and capsules that are brewed from a mixture of chemicals, injectable therapies like hormones and genetically engineered proteins are not covered by the Hatch-Waxman Act, the 1984 law that laid the foundation for the nation’s generic drug industry. That has left brand-name biotech manufacturers with the hope of monopolies well into the future.

h1

105759377831450745

July 7, 2003

Antibacterials: a dying trade
: Despite strong worldwide demand for effective antibacterial products, sustaining growth within this segment will become a challenging task for major pharmaceutical companies. Currently only six marketed drugs have sales of greater than $1 billion and by 2011, 12 out of 29 key products will face patent expiry. A relatively sparse R&D pipeline will do little to replace older products.